Dental News - New study findings on Xeal and TiUltra surfaces with All-on-4 treatment concept

Nobel Biocare

Thu. 16. June 2022

save

As director of both the research and development department and the oral hygiene department at MALO CLINIC in Lisbon in Portugal, Dr Miguel de Araújo Nobre has more than 20 years’ experience as a clinical researcher and has co-authored over 100 scientific publications in international peer-reviewed journals and six book chapters. In this interview, he outlines the promising results of a pilot study that he and Dr Ana Ferro, head of the department of oral surgery, periodontics and implant treatment at the clinic, are currently conducting on Nobel Biocare’s Xeal abutment surface and TiUltra implant surface with All-on-4 treatment.

Dr de Araújo Nobre, what made you adopt the Xeal and TiUltra surfaces?
We have previous experience using anodised surfaces—we started using Nobel Biocare’s TiUnite implant surface a long time ago—and have up to 18 years’ follow-up data that prove that it is a reliable long-term option. For these new Xeal and TiUltra surfaces, we scrutinised the research beforehand and were particularly interested in the Mucointegration concept. From our point of view, it fills a gap in implant dentistry in relation to the peri-implant complex.

Dr Miguel de Araújo Nobre. (Image: Nobel Biocare)

Can you tell us about the aim of this pilot study?
The aim of the study is to evaluate the clinical outcomes, at three years, of full-arch rehabilitations conducted with the All-on-4 treatment concept using NobelParallel Conical Connection implants with the TiUltra surface and Multi-unit Abutments with the Xeal surface. It’s an ongoing study with 16 patients.

Could you summarise the key results?
We achieved a 100% survival rate for both implant and abutment with a mean marginal bone loss of just 0.46 mm after one year. Though some mechanical complications occurred with provisional prosthesis screw fractures, there was an absence of biological complications and a good and stable soft tissue response. In a nutshell, these are good results.

We have learned over the years that, if a stable maintenance protocol is kept up, the majority of implant failures normally occur in the first or second year of follow-up. Registering a 100% survival rate during the first year of follow-up is very promising. From a researcher’s point of view, the one-year survival rate is an important indicator of potential long-term success.

Regarding the marginal bone loss results, what can clinicians learn from this, particularly regarding long-term outcomes?
Often the marginal bone loss level is a predictor of long-term outcome success. When you place an implant, the implant failure likelihood tends to decrease over time. At the same time, the probability of pockets of marginal bone loss increases. This is the difference between early and late implant failure. For this study, we recorded an average of 0.46 mm of marginal bone loss after one year—0.57 mm in the maxilla and 0.19 mm in the mandible. From our perspective, this was a very pleasant surprise.

Editorial note:

EuroPerio attendees can find out more about Nobel Biocare’s products at booth E.01. Watch a clinical case video of the All-on-4 treatment concept from the study (case courtesy of Dr Ana Ferro).

To post a reply please login or register

Nobel Biocare commences new era with Xeal and TiUltra surfaces

COLOGNE, Germany: Nobel Biocare has invited dental professionals to join the Mucointegration era with the launch of the Xeal and TiUltra surfaces at IDS ...

Nobel Biocare launches Xeal and TiUltra surfaces in US

YORBA LINDA, Calif., U.S.: Nobel Biocare is inviting dental professionals to join what it calls the Mucointegration era with the launch of its Xeal and ...

“Science, stability, success”: Dr Graham Carmichael discusses Xeal and TiUltra surfaces

An award-winning clinician, researcher and director at the Brånemark Centre in Perth in Australia, Dr Graham Carmichael is a consultant prosthodontist and ...

Nobel Biocare presents new On1 restorative concept at EAO

PARIS, France: At the congress of the European Association for Osseointegration (EAO), currently being held in Paris, dental implants manufacturer Nobel ...

CIDRR journal publishes scientific evidence on Nobel Biocare’s latest surface innovations

MADRID, Spain: With the launch of its Xeal abutment surface and TiUltra implant surface this year, Nobel Biocare recently initiated the Mucointegration era ...

Review confirms clinical success of Nobel Biocare’s TiUnite surface

ZURICH, Switzerland: A new systematic review and meta-analysis has provided evidence confirming the efficacy of Nobel Biocare implants with the TiUnite ...

Innovative dental implant treatment taken to Easter Island on a humanitarian mission

RAPA NUI, Chile: Dental implantology experts and the Foundation for Oral Rehabilitation (FOR) have taken a new treatment solution for edentulism to Rapa ...

Implant treatment of the fully edentulous patient—contribution of digital techniques

An 82-year-old patient presented for complete rehabilitation. The existing maxillary bridge showed Grade III mobility and the residual mandibular teeth ...

Interview: A new splash of life

Numerous innovative restorative and aesthetic dental solutions, which are considered an industry standard today, have been brought to market by Nobel ...

Market share of value and discount implant solutions to increase in Asia Pacific

BURNABY, British Columbia, Canada: According to a new market report by iData Research, a leading provider of international dental market research, the Asia ...

Happy birthday, creos! Nobel Biocare celebrates a decade of excellence in regenerative solutions

KLOTEN, Switzerland: In the ever-evolving world of dental regenerative solutions, Nobel Biocare has consistently set the benchmark for innovation and ...

Education

On-demand
webinar